Showing posts with label Alzheimer's disease. Show all posts
Showing posts with label Alzheimer's disease. Show all posts

Tuesday, February 5, 2013

Donepezil Improves Dementia With Lewy Bodies

Dementia with Lewy bodies (DLB) is a type of dementia less common than Alzheimer's disease.  However, Lewy bodies (brain neuron deposits of the proteins alpha-synuclean and ubiquitin) are found in up to 10 to 15% of individuals dying of dementia.

DLB is known to deplete brain acetylcholine and dopamine neurotransmitter levels in the brain.  This leads to a clinical syndrome characterized by both cognitive decline and motor symptoms similar to Parkinson's disease.

DLB may be difficult to distinguish from Alzheimer's disease but typically exhibits fluctuations in cognitive function, visual hallucinations, visuoperceptual impairment and concurrent motor symptoms.

Few clinical trials have targeted DLB due to it's relative infrequency and diagnostic classification.  A Japanese study of 148 subjects with DLB recent found support for the effectiveness of the Alzheimer's drug donepezil.

Mori and colleagues conducted a randomized clinical trial with the following key elements in the research design:

  • Subjects: Met probable DLB diagnosis using structured criteria, no Parkinson's disease diagnosis more than one year before onset of dementia, no evidence of focal vascular disease on CT or MRI
  • Drug administration: Double-blind randomization of donepezil 3 mg, 5 mg, 10 mg or placebo for 12 weeks
  • Outcome measures: Minimental state exam (MMSE) scores, attention, executive function and visuoperceptual cognitive function from the Wechsler Memory Scale-Revised (WMS-R), tests for verbal fluency and agnosia.  Ten behavioral domains were also assessed.  Clinicians blind to treatment rated global clinical status.  Caregivers rated burden of care.  Motor symptoms were assessed using the Unified Parkinson's Disease Rating Scale.
  • Statistical analysis: Last observation carried forward analysis on all subjects with at least one valid post-treatment measurement


This trial found significant therapeutic effects for donepezil across a variety of DLB disease domains (doses statistically associated with improvement compared to placebo)

  • Minimental status exam: 5 and 10 mg
  • Clinician global improvement scores: 3, 5 and 10 mg
  • Behavioral scores for hallucinations, cognitive fluctuation, delusions, apathy and depression: 5 and 10 mg
  • Caregiver burden scores: 10 mg



Photo of two brain Lewy Bodies 
Donepezil was fairly well tolerated in this study sample with 3 to 8% of the active drug groups discontinued due to adverse effects.  This rate was not different than placebo withdrawals.

The authors conclude that their study provides support for the effectiveness of donepezil across a variety of clinical domains.  They note the study supports using a 10 mg dose if tolerated.  

Recruiting clinical sample sizes sufficient to study treatment options in DLB is not easy.  This makes the current study an important one.  Additional clinical trials have also found support for rivastigmine, galantamine and memantine for DLB.  However, there is likely to be a paucity of clinical trials for DLB in the future relative to the number of trials in Alzheimer's dementia. 

Individuals with additional interest in this clinical trial can access the free full-text of the study by clicking on the PMID link below.

Photo of cinnamon teal duck is from the author's files.

Photo of Lewy bodies from the Wikipedia Commons file authored by Dr. Andreas Becker

Mori E, Ikeda M, Kosaka K, & Donepezil-DLB Study Investigators (2012). Donepezil for dementia with Lewy bodies: a randomized, placebo-controlled trial. Annals of neurology, 72 (1), 41-52 PMID: 22829268

Monday, February 4, 2013

Oxytocin and Grandparent Attachment

I a previous post I summarized a review of the emerging research field of oxytocin and human attachment.

This research supports a key role for oxytocin in reproduction and parental infant bonding.   The above mentioned review emphasized the important role of gender, genetic and early environment in the effect individual human variation in oxytocin response.

One additionally related important research topic relates to the effect of ageing on oxytocin-related systems.  Huffmeijer and colleagues from Leidenand Eramus University recently published a review on this topic in the journal Gerontology.

The authors of this review note the importance of oxytocin in parent-infant bonding and argue by extension this system is probably important in grandparent-grandchild bonding.

However, the review notes there is a paucity of research focusing on the age-related effects on the human oxytocin system.  There is extensive data linking oxytocin with prosocial maternal and paternal behavior towards infants.  There is no research examining the role of the oxytocin system in grandparents.

The limited study of the animal human oxytocin system and ageing points to a few key findings:
  • Animal studies support a decreased level of oxytonergic activity with age--the results in humans on this area have been mixed
  • Older animals with reduced oxytocin activity still have a prosocial response to exogenously administered oxytocin
  • The brain amygdala-limbic system has rich neural connections with oxytocin-related neurons but  amygdala volumes decline with age (this effect is more pronounced in Alzheimer's disease)
  • With ageing, amygdala connectivity increases with frontal regions but decreases with posterior brain regions
  • Age-related amygdala changes may contribute to the decline in emotional recognition with age seen in humans

The authors conclude that the effect of oxytocin in older humans cannot simply be assumed to be the same as in younger adults.   Due to the effects of ageing, oxytocin response (and adverse effects) may be quite different in elderly humans.

Oxytocin research needs to include a focus on the elderly including grandparent-grandchild bonding.  Many children are primarily raised by their grandparents.  Understanding the dynamics of the oxytocin system in the elderly has practical implications for many families.

Readers with more interest in this topic are directed to the free full text manuscript that can be accessed by the PMID

Photo of reddish egret from the author's files.

Huffmeijer R, van Ijzendoorn MH, & Bakermans-Kranenburg MJ (2013). Ageing and oxytocin: a call for extending human oxytocin research to ageing populations - a mini-review. Gerontology, 59 (1), 32-9 PMID: 22922544

Tuesday, January 15, 2013

Fat Gene (FTO) Linked to Alzheimer's Disease Risk

The relationship between obesity and risk for Alzheimer's disease is a controversial area of research.

Several studies have found a prospective increase in risk for Alzheimer's disease in those with obesity.  However, the association has been inconsistent.  Some studies have even found a reduced risk of later Alzheimer's disease in overweight populations.

One method to further investigate the possible obesity-Alzheimer's risk association is through direct genetic studies of genes known to be related to obesity.

Christiane Reitz and colleagues from the U.S. National Institute on Aging recently published this type of study in the journal PLOS One.

They focused on polymorphisms of the Fat and Obesity-Associated (FTO) gene.  The FTO gene is located on the q arm of human chromosome 15.  Polymorphisms associated with FTO intron 1, intron 2 and exon 2 have been linked to increased rates for obesity and also have some evidence of being linked to risk for Alzheimer's disease.

To study this issue in more detail, Reitz and colleagues conducted a single nucleotide protein (SNP) analysis of the FTO gene in Alzheimer's disease subjects and controls.  Two independent samples with a combined sample size approaching 3000 subjects were used in the SNP analysis. Additionally, they conducted a FTO gene expression analysis of Alzheimer's disease cases that had been confirmed by brain neuropathological analysis. 

The key finds from this genetic study were:
  • Eight FTO SNP regions were linked to variation in risk for Alzheimer's disease
  • Eleven FTO haplotypes were identified that significantly contributed to risk for Alzheimers's disease
  • Gene expression studies in brain tissue of Alzheimer's disease subjects showed lower FTO gene expression compared to controls
The authors note their study findings "confirm the association between genetic variation in Intron 1, Exon 2 or Intron 2 in the FTO gene and AD".  (AD=Alzheimer's disease).

They propose several mechanisms for this association.  FTO gene status increases risk for hyperinsulinemia and type II diabetes, known risk factors for Alzheimer's disease.  They note a second potential mechanism where FTO gene status contributes to Alzheimer's disease by a vascular pathology (i.e. hypertension, lipid dysregulation, atherosclerosis).  Finally, they note obesity increases inflammatory markers by increasing adipokines and cytokines that may contribute to risk or severity of Alzheimer's disease.

This is an important study in the ongoing search to understand the effect of obesity on Alzheimer's disease risk.  Exploring genetic mechanisms is a promising approach to complement  epidemiological risk factor studies to advance our understanding of Alzheimer's disease. 

Photo of willet from the author's files. 

Reitz C, Tosto G, Mayeux R, Luchsinger JA, & the NIA-LOAD/NCRAD Family Study Group and the Alzheimer's Disease Neuroimaging Initiative (2012). Genetic Variants in the Fat and Obesity Associated (FTO) Gene and Risk of Alzheimer's Disease. PloS one, 7 (12) PMID: 23251365

Monday, January 14, 2013

Lifestyle Factors and Risk of Alzheimer's Dementia

The number of individuals suffering from Alzheimer's disease is rapidly increasing throughout the developed world.

A significant portion of this increase is explained by demographic trends as the Baby Boomer generation progresses through the high-risk age categories for Alzheimer's and other dementia.

It is important to understand potentially modifiable lifestyle risk factors that may stimulate a valid public health prevention program.

An important recent study examined lifestyle factors and risk for dementia among a cohort of Japanese American men.  

Gelber and colleagues followed a cohort of 3468 men over a period of 25 years.  The study focussed on the emergence of dementia including both Alzheimer's disease and vascular dementia.

The key components of the study design in this study included:

  • Cohort characteristics: Men of Japanese ancestry born between 1900 through 1919 living in Oahu, Hawaii
  • Dementia diagnosis: The cohort received regular neuropsychological screening with cognitive deficits prompting neurologist referral.  The study neurologist and two physicians made decisions about a diagnosis of Alzheimer's disease or vascular dementia using clinical information, neuropsychological testing, blood tests and brain imaging (CT or MRI) results. 
  • Modifiable risk factor variables: BMI category, smoking status, physical activity level, dietary intake and alcohol consumption.  A global lifestyle low-risk group was identified that demonstrated the presence of a low risk on all four modifiable risk factors: BMI less than 22.6, never smoking, 3 or more hours per week of physical activity and high dietary score (more vegetable/fruit intake and moderate alcohol intake).

A total of 223 cases of dementia were identified during the follow up period.  The majority were assigned a diagnosis of Alzheimer's dementia (n=117), with vascular dementia a close second in frequency (n=78).  Twenty eight cases were given another cause for dementia.

High BMI, smoking and low physical activity all increased risk for overall dementia diagnosis with the following estimates for odds ratio of those with risk factor compared to those without:

  • BMI: Odds ratio= 1.87
  • Smoking: Odds ratio= 1.48
  • Low physical activity: Odds ratio= 1.59

Diet score did not show a statistically significant association with overall dementia risk.

However, when specific type of dementia was examined, none of the individual lifestyle factors proved to be statistically associated with Alzheimer's disease risk.  BMI, smoking status and low physical activity were individually linked to increased risk for vascular dementia at odds ratios estimated at high levels than in the overall dementia group.

Men positive for all four lifestyle factors showed a 64% reduction in dementia risk, but this was primarily in reduction of risk for vascular dementia.

Finding no association between lifestyle factors and risk for Alzheimer's disease is somewhat discouraging.  It suggests that genetic factors, i.e. APOE gene status, may be resistant to the moderating effects of lifestyle changes.  

However, the study supports promotion of a healthy lifestyle approach in mid-life to reduce risk of vascular dementia.  Adopting all four factors in a healthy lifestyle promotes a significantly reduced risk of later dementia diagnosis.

Readers with a more detailed interest in the study can access the free full text article by clicking on the PMID link below.

Photo of burrowing owl from the author's files. 

Gelber RP, Petrovitch H, Masaki KH, Abbott RD, Ross GW, Launer LJ, & White LR (2012). Lifestyle and the risk of dementia in Japanese-american men. Journal of the American Geriatrics Society, 60 (1), 118-23 PMID: 22211390

Friday, January 11, 2013

Brain MRI and Enhanced Alzheimer's Drug Trials

Clinical research trials in Alzheimer's disease are hampered by insensitive outcome measures.

This effect results in the need for very expensive large sample sizes trial protocols.

Current state-of-the-art Alzheimer's trials frequently use the Minimental Status Exam (MMSE) or the cognitive subscale of the Alzheimers disease assessment scale (ADAS Cog).  These measures are imperfect and imprecise, often requiring a minimum of 200 to 300 subjects to be enrolled.

One strategy to improve Alzheimer's disease clinical trial methodology is to use more sensitive brain imaging markers to measure therapeutic response.

Ai-Ling Lin and colleagues from the University of Texas Health Science Center at San Antonio have recently reviewed the clinical research literature on this topic (citation below).  They reviewed research studies on cognitive decline using a number of brain imaging techniques including:

  • High-resolution magnetic resonance imaging (MRI)
  • Diffusion tensor imaging (DTI)
  • Functional MRI (fMRI)
  • Cerebral blood flow estimation using arterial spin labeling MRI (ASL-MRI)
  • Single-photon emission computed tomography (SPECT)
  • Magnetic resonance imaging spectroscopy
  • Positron emission tomography (PET)

Obviously, there are many imaging tools available as potential biomarkers in Alzheimer's disease.  A key research issue is to find the most sensitive tool (or set of tools) that is valid and financially feasible.

The review covers research findings related to brain imaging markers in cognitively normal adults with genetic markers for Alzheimer's disease (APOE gene), mild cognitive impairment, the conversion of mild cognitive impairment to Alzheimer's disease and those diagnosed with Alzheimer's disease.  For the purpose of this post I will focus on their findings in those who have Alzheimer's disease.

Alzheimer's disease produces a marked increase in the volume of global and focal brain atrophy.  They note in their study the relative magnitude of yearly brain volume reduction in the 70 to 80 year age group in Alzheimer's disease compared to those without Alzheimer's disease (controls).  The data from high-resolution MRI studies show:
  • Yearly global atrophy rate: 2 to 3% in Alzheimer's disease, 0.3% to 0.5% controls
  • Yearly hippocampus atrophy rate: 3.0 to 5.9% in Alzheimer's disease, 1.0% to 1.7% in controls
  • Yearly entorhinal cortex: 7.2% to 8.4% in Alzheimer's disease, 1.4% to 2.9% in controls

The entorhinal cortex region is a key region in assessing Alzheimer's disease related brain atrophy.  The entorhinal cortex region is highlighted in the figure on the left in blue.


Brain changes in Alzheimer's disease are also found in the default mode network assessed by MRI functional connectivity imaging and in cerebral blood flow using ASL-MRI.

The authors conclude that multimodal MRI (high-resolution MRI, functional connectivity MRI and arterial spin labeling MRI) holds promise as a powerful strategy to measure therapeutic effects in experimental drug study clinical trials for Alzheimer's disease.  They note these techniques will require validation against currently used primary outcome measures.  

However, because of the sensitivity of multimodal MRI, clinical trials may be able to reduce sample sizes to only about 20 to 25 subjects.  

This enhancement would be a big leap in Alzheimer's drug research and development.  It holds the promise of speeding up the clinical trial process and allowing for the study of more potential therapeutic compounds.

Photo of fire-tufted barbet from the San Diego Zoo is from the author's files.

Entorhinal cortex figure is a screen shot from the iPad app 3D Brain.

Lin AL, Laird AR, Fox PT, & Gao JH (2012). Multimodal MRI neuroimaging biomarkers for cognitive normal adults, amnestic mild cognitive impairment, and Alzheimer's disease. Neurology research international, 2012 PMID: 21949904